Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease

Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease

Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn's disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.

Elmentve itt :
Bibliográfiai részletek
Szerzők: Anjie Suzanne I
D'Haens Geert R.
Baert Filip
Bossuyt Peter
Hoentjen Frank
Clasquin Esme
Molnár Tamás
Lowenberg Mark
Vermeire Severine
Panetta J. Carl
Dervieux Thierry
Dokumentumtípus: Cikk
Megjelent: 2026
Sorozat:INFLAMMATORY BOWEL DISEASES 32 No. 2
Tárgyszavak:
Gasztroenterológia és hepatológia
doi:10.1093/ibd/izaf255

mtmt:36438900
Online Access:http://publicatio.bibl.u-szeged.hu/39328
Leíró adatok
Tartalmi kivonat:Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn's disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.
Terjedelem/Fizikai jellemzők:390-393
ISSN:1078-0998

Hasonló tételek